GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) of -$59.64 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecrease · last filed 2012-05-04
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$59.64M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $89.88M, a 160.26% increase year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $149.14M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was -$27.02M, a 125.80% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2011 was $75.83M, a 99.21% increase from fiscal 2010.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2010 was $38.06M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$71.33M, a 186.91% decline from fiscal 2008.
- GILEAD SCIENCES, INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax (deprecated 2012-01-31) for fiscal 2008 was $82.07M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | -$59.64M 10-Q · filed 2012-05-04 | $30.23M derived: sum of 2 quarters · filed 2012-05-04 | $179.37M derived: sum of 3 quarters · filed 2012-05-04 | $152.35M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $89.88M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $239.01M derived: sum of 2 quarters · filed 2012-02-23 | $212.00M derived: sum of 3 quarters · filed 2012-02-23 | $75.83M 10-K · filed 2012-02-23 |
| 2011-09-30 | $149.14M 10-Q · filed 2011-11-04 | $122.12M derived: sum of 2 quarters · filed 2011-11-04 | -$14.05M 10-Q · filed 2011-11-04 | $20.49M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | -$27.02M 10-Q · filed 2011-08-05 | -$163.19M 10-Q · filed 2011-08-05 | -$128.65M derived: sum of 3 quarters · filed 2012-05-04 | -$327.63M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | -$136.17M 10-Q · filed 2012-05-04 | -$101.64M derived: sum of 2 quarters · filed 2012-05-04 | -$300.61M derived: sum of 3 quarters · filed 2012-05-04 | -$195.89M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $34.53M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$164.44M derived: sum of 2 quarters · filed 2012-02-23 | -$59.72M derived: sum of 3 quarters · filed 2012-02-23 | $38.06M 10-K · filed 2012-02-23 |
| 2010-09-30 | -$198.98M 10-Q · filed 2011-11-04 | -$94.25M derived: sum of 2 quarters · filed 2011-11-04 | $3.53M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $104.72M 10-Q · filed 2011-08-05 | $202.51M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $97.79M 10-Q · filed 2011-05-09 | |||
| 2009-12-31 | -$71.33M 10-K · filed 2012-02-23 | |||
| 2008-12-31 | $82.07M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |